Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | 0.00% | +23.08% | +111.76% |
18/04 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
18/04 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.54M 1.13B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.92B | Net income 2025 * | -26M -2.17B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.84
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Imunon, Inc.
1 week | +23.08% | ||
Current month | -12.20% | ||
1 month | +2.86% | ||
3 months | +156.82% | ||
6 months | +45.45% | ||
Current year | +111.76% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Tardugno
CHM | Chairman | 73 | 03/07/03 |
Jeffrey Church
DFI | Director of Finance/CFO | 67 | 06/10/06 |
Sebastien Hazard
CTO | Chief Tech/Sci/R&D Officer | 53 | 11/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 08/21/08 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 08/11/08 |
James Dentzer
BRD | Director/Board Member | 57 | 03/22/03 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.44 | 0.00% | 49,331 |
25/24/25 | 1.44 | +10.77% | 69,402 |
24/24/24 | 1.3 | -2.26% | 32,477 |
23/24/23 | 1.33 | +4.72% | 51,141 |
22/24/22 | 1.27 | +8.55% | 66,052 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+111.76% | 13.54M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IMNN Stock